努阿克激酶:信号机制和治疗应用
Nicole M Cullen1, Peter Rosston2, Bakhtawar Tufail1
1Department of Medicine, Section of Hematology and Oncology, Tulane University School of Medicine, New Orleans, LA 70112, USA.
The Journal of biological chemistry
|August 7, 2025
概括
新型酶NUAK1和NUAK2在疾病中至关重要,但缺乏向药物. 本综述探讨了它们的作用和开发NUAK1和NUAK2信号通路的特定抑制剂的治疗潜力.
科学领域:
- 生物化学和分子生物学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 新型 (NUAK) 激酶1和2是AMP激活的蛋白相关激酶,涉及癌症和其他疾病.
- 大多数人体激酶,包括NUAK1和NUAK2,在有限的向治疗中仍未得到充分研究.
- 对于NUAK1和NUAK2信号传递的选择性抑制剂有很大的需求.
研究的目的:
- 审查NUAK1和NUAK2的结构,调节和生物作用.
- 探索NUAK1和NUAK2在癌症和非癌症组织中的表达特征.
- 评估针对NUAK激酶信号通路的治疗潜力.
主要方法:
- 关于蛋白质结构,上游调节器和下游目标的文献综述.
- 在各种恶性瘤和非癌症中分析NUAK1和NUAK2表达.
- 在临床前和临床研究中对NUAK激酶的现有小分子抑制剂的概述.
主要成果:
- 努阿克1和努阿克2在癌症进展和其他疾病中起作用.
- 癌症和非癌症组织之间的表达特征不同.
- 几种向NUAK激酶的小分子抑制剂在临床前模型中表现有前途,其中一种是在临床试验中.
结论:
- 准NUAK激酶信号通路为各种疾病,特别是癌症提供了治疗潜力.
- 选择性小分子抑制剂是利用这种治疗价值的关键.
- 为了开发有效的治疗方法,需要对NUAK1和NUAK2进行进一步的研究.
相关概念视频
Amplifying Signals via Enzymatic Cascade
8.8K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.8K
Transducer Mechanism: Enzyme-Linked Receptors
2.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.8K
MAPK Signaling Cascades
6.1K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.1K
Interactions Between Signaling Pathways
6.4K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K
PI3K/mTOR/AKT Signaling Pathway
4.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.0K
The JAK-STAT Signaling Pathway
9.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.2K


